Produkten har lagts i din varukorg Visa varukorgenTill kassan
Din webbläsare stöds ej. För bästa upplevelsen rekommenderas en nyare version eller en annan webbläsare.
För att ge dig bättre service använder vi cookies. Genom att fortsätta på sidan godkänner du vår användning av cookies.

PD-L1 Clone: CAL10 1,0 ml

BC-ACI3171C
Produktfråga

Vad vill du veta om PD-L1 Clone: CAL10 1,0 ml?

Skicka

Beskrivning

PD-L1

Programmed death ligand 1 (PD-L1, also known as CD274) inhibits tumor-reactive T-cells via binding to the programmed death-1 (PD-1) receptor, rendering tumor cells resistant to CD8+ T cell-mediated lysis (1). Studies have shown that the inhibitory receptor PD-1 is expressed on tumor-infiltrating lymphocytes (TIL) while PD-L1 is expressed on tumor cells. Assessment of PD-L1 expression in combination with CD8+ TIL density may be a useful predictive metric in multiple cancers, including stage III NSCLC, hormone receptor negative breast cancer and sentinel lymph node melanoma (2-4). Clinical trials utilizing humanized chimeric antibodies that block inhibitory checkpoints, such as anti-PD-1 and anti-PD-L1, have demonstrated delayed tumor growth and increased survival (5). While identification of PD-L1 overexpression by IHC is not yet standardized, it has become increasingly important to identify these tumors, as a directed therapy may improve clinical outcomes in these patients (6). In cutaneous melanoma, the targeting of PD-1/PD-L1 has provided meaningful clinical benefit for patients in just the past 5-10 years (7). The use of IHC for protein identification, along with novel therapies, such as checkpoint inhibitors and vaccines, are generating new options for the treatment of cancer patients. The PD-L1 [CAL10] clone does not cross react with PD-L2.

 

Intended Use

IVD

Format

Concentrate, Predilute

Volume

0.1 ml, 1.0 ml, 6.0 ml

Source

Rabbit Monoclonal

Clone

CAL10

Isotype

IgG1

Localization

Membranous/cytoplasmic

Positive Control

Lung adenocarcinoma or tonsil

 

Läs mer ...Stäng